Cash from Operations (Quarterly) Chart

View Cash from Operations (Quarterly) for COCP.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (Quarterly) Chart
Start Trial

Historical Cash from Operations (Quarterly) Data

View and export this data back to 2008. Start Trial.
Date Value
June 30, 2026 -2.536M
March 31, 2026 -2.34M
December 31, 2025 -1.836M
September 30, 2025 -1.551M
June 30, 2025 -2.268M
March 31, 2025 -2.939M
December 31, 2024 -2.550M
September 30, 2024 -4.310M
June 30, 2024 -3.638M
March 31, 2024 -4.503M
December 31, 2023 -2.864M
September 30, 2023 -3.051M
June 30, 2023 -5.785M
March 31, 2023 -3.111M
December 31, 2022 -5.300M
September 30, 2022 -8.896M
June 30, 2022 -3.809M
March 31, 2022 -3.91M
December 31, 2021 -2.596M
September 30, 2021 -5.405M
June 30, 2021 -2.662M
March 31, 2021 -1.77M
December 31, 2020 -3.014M
September 30, 2020 -3.188M
June 30, 2020 -1.893M
Date Value
March 31, 2020 -2.188M
December 31, 2019 -1.232M
September 30, 2019 -1.323M
June 30, 2019 -1.026M
March 31, 2019 2.018M
December 31, 2018 -1.692M
September 30, 2018 -2.254M
June 30, 2018 -2.020M
March 31, 2018 -2.078M
December 31, 2017 -1.193M
September 30, 2017 -2.401M
June 30, 2017 -1.234M
March 31, 2017 -2.052M
December 31, 2016 -1.827M
September 30, 2016 -2.781M
June 30, 2016 -5.151M
March 31, 2016 -4.042M
December 31, 2015 -2.925M
September 30, 2015 -2.815M
June 30, 2015 -2.480M
March 31, 2015 -1.559M
December 31, 2014 -1.510M
September 30, 2014 -1.107M
June 30, 2014 -1.366M
March 31, 2014 -1.78M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Quarterly) Range, Past 5 Years

View Cash from Operations (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Quarterly) Benchmarks

View Cash from Operations (Quarterly) Benchmarks
Start Trial
CNBX Pharmaceuticals, Inc. -0.0477M
GB Sciences, Inc. --
Arvinas, Inc. -48.30M
Fulcrum Therapeutics, Inc. -16.04M
Definium Therapeutics, Inc. -52.33M

Cash from Operations (Quarterly) Related Metrics